188 related articles for article (PubMed ID: 28433540)
1. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.
Teymourzadeh A; Mansouri S; Farahmand L; Hosseinzade A; Majidzadeh-A K
Clin Breast Cancer; 2017 Oct; 17(6):403-407. PubMed ID: 28433540
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
3. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
[TBL] [Abstract][Full Text] [Related]
8. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
[TBL] [Abstract][Full Text] [Related]
9. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
10. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
11. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer.
Zhao Y; Deng C; Lu W; Xiao J; Ma D; Guo M; Recker RR; Gatalica Z; Wang Z; Xiao GG
Mol Med; 2011; 17(11-12):1233-41. PubMed ID: 21826373
[TBL] [Abstract][Full Text] [Related]
12. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance.
Yin L; Wang ZY
Steroids; 2016 Jul; 111():95-99. PubMed ID: 26884313
[TBL] [Abstract][Full Text] [Related]
13. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
[TBL] [Abstract][Full Text] [Related]
14. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.
Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R
Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287
[TBL] [Abstract][Full Text] [Related]
16. Advances in the understanding of the structure and function of ER-α36,a novel variant of human estrogen receptor-alpha.
Rao J; Jiang X; Wang Y; Chen B
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):231-7. PubMed ID: 21888973
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
[TBL] [Abstract][Full Text] [Related]
18. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.
Yin L; Zhang XT; Bian XW; Guo YM; Wang ZY
PLoS One; 2014; 9(9):e107369. PubMed ID: 25203051
[TBL] [Abstract][Full Text] [Related]
19. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
Zhang J; Li G; Li Z; Yu X; Zheng Y; Jin K; Wang H; Gong Y; Sun X; Teng X; Cao J; Teng L
Steroids; 2012 May; 77(6):666-73. PubMed ID: 22402113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
